Neurocrine Biosciences | NBIX - Ebitda



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 14.04B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


Ebitda 更改 日
AbbVie USD 3.69B 1.68B 2026-03
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
ALKERMES USD 139.22M 58.96M 2026-06
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amgen USD 3.86B 1.28B 2026-03
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Cytokinetics USD -169.32M 19.48M 2026-03
Exelixis USD 255.4M 2.89M 2026-06
Gilead Sciences USD 3.51B 489M 2026-03
Halozyme Therapeutics USD 328.81M 109.24M 2026-06
Incyte USD 778.57M 410.6M 2026-06
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Pfizer USD 6.01B 18M 2026-06
Prothena USD 25.98M 65.51M 2026-03
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Repligen USD 43.77M 3.76M 2026-06
Rigel Pharmaceuticals USD -4.17M 798K 2023-09
Sarepta Therapeutics USD 375.48M 627.68M 2026-03
Teva Pharmaceutical Industries USD 474M 581M 2026-06
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06